When researching CBD one of the most common things you hear is how it works on the endocannabinoid system. When coming to understand the endocannabinoid system you learn about CB1 and CB2 receptors. These cannabinoid receptors are protein molecules that receive chemical signals from outside the cell, once they receive the signal, they spring into action. This is what causes all the pain relieving and anti-inflammatory effects.
In limited years of research, scientists have found a new molecule, GPR55, which many believe is also a cannabinoid receptor. This could potentially be the CB3 receptor. We know that the GPR55 molecule is found throughout our brain, in the hippocampus, cerebellum, thalamus, parts of the spleen, adrenal glands, as well as other remote areas of the body. GPR55 has also been found in cancer cells which suggests why CBD can be used a cancer suppressant. However, so far scientists have been having a difficult time directly targeting the GPR55 receptor. Once they can it will allow better strain-matching for therapeutic uses.
During studies it was found that the GPR55 receptor becomes active from a variety of plant, synthetic, and real cannabinoids. Conversely, it has been found in-active in response to cannabidiol. This helps illustrate how CBD blocks some receptors while supporting others to naturally create and maintain the body’s natural homeostasis. So far, research studies on GPR55 have included; osteosis, when it has been found to slow bone degeneration; diabetics, where the receptor regulated insulin levels; and immune cell regulation.
Cannabinoids have so much to offer as a natural healer, but unfortunately, having cannabis as a schedule 1 drug makes it very difficult to research. If decriminalized, universities, hospitals, and other research facilities could research some of the plentiful advantages of hemp. Furthermore, they can explore this newly found receptor that could help benefit our current understanding of the endocannabinoid system.